DNA Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 5.89%, SMA50 6.53%, SMA200 -7.03%). The stock’s 14-day RSI is 54.48 (neutral), while the ATR of 0.7 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -44.77% below its high and over 94.2% above its low. Average 10-day trading volume of 1.81 million shares is slightly above the 3-month average of 1.22 million, indicating heightened recent market interest.

Ginkgo Bioworks Holdings, Inc. generated EPS of -$6.23 over the past year. Five-year average earnings growth is -27.97%. The latest quarter delivered EPS of -$1.39. The next quarter is forecast at -$1.46. Next year's EPS is expected at $30.33. Analyst sentiment is bearish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 2 Sell rating and 0 Strong Sell ratings. Price targets range from $14.00 to $9.00. The high target offers 67.87% upside. The low target suggests 7.91% downside. The mean target is $10.67. This offers 27.94% upside. Ginkgo Bioworks Holdings, Inc. earnings surprise history is a mixed track record. The quarter that ended May 07, 2026, missed forecasts by 14.77%. The prior quarter beat by -21.11%. Over the last six quarters, Apple has recorded several small beats. These include 25.52% in February 25, 2025.

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) closed at $8.57 USD, gaining $0.23 (2.76%) from the previous close of $8.34. The stock is currently mid-range between its 52-week high and low $5.37 and $17.58. With a market capitalization of about $559.83 million, Ginkgo Bioworks Holdings, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.78). Key stats such as the average daily volume over the past year has been around 1.25 million shares, volume is running light vs its 52-week average. Headquartered in Boston, MA, Ginkgo Bioworks Holdings, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jason Kelly, the company employs approximately 834 people and listed since April 19, 2021. Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming.

Ginkgo Bioworks Holdings, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$7.93. This means the shares are trading below this model’s fair value.

Ginkgo Bioworks Holdings, Inc. has 47.09 million shares outstanding. The public float is 37.81 million shares, elevated short interest at 14.63% of float. This equals 6.71 million shares. The short ratio is 4.24 days. Institutional investors hold 84.85% of the float. Insiders own 6.77%. DEKKERS MARIJN E holds 5.52 million shares, Sankar Shyam has 2.36 million shares and SLOAN HARRY has 718.54 thousand shares. Over the past six months, insider transactions show net selling. They sold 544.69 thousand shares across 13 transactions.

Ginkgo Bioworks Holdings, Inc. trades at a P/E ratio of -1.63, slightly below the S&P 500 average, with a price-to-sales ratio of 3.86 and a price-to-book ratio of 1.12 suggesting the stock is closer to book value. The P/FCF stands at -2.97, also above market averages.

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) shares are flat 8.66% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Ginkgo Bioworks Holdings, Inc. trading at a premium to the broader market with a P/E of -1.63. Analyst sentiment is cautious, with the majority of ratings in Sell territory and a mean price target of $7.52, suggesting -9.83% downside. Our AI forecast model points to short-term strength (15.59% over two weeks), a medium-term rise (132.61% over three months), and a longer-term loss (-16.07% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Ginkgo Bioworks Holdings, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 15.59%, with price expected at $9.64 by May 26, 2026, within a range of $8.89 to $10.38 3-Month Outlook: Projected rise of 132.61%, reaching $19.40 by August 10, 2026, with a range of $18.60 to $20.01. 1-Year Outlook: Projected loss of -16.07%, with price at $7.00 by May 12, 2027, within a range of $0.00 to $6.25.